Alla studier
Aktiv men inte rekryterandeFAS1, FAS2INTERVENTIONELL

A Study of [177Lu]Lu-DOTA-TATE in Newly Diagnosed ES-SCLC Patients in Combination With Carboplatin, Etoposide and Atezolizumab

This study is looking into a new treatment for a serious type of lung cancer called Extensive Stage Small Cell Lung Cancer (ES-SCLC). The new treatment combines a special radioactive medicine, [177Lu]Lu-DOTA-TATE, with standard chemotherapy (carboplatin and etoposide) and another anti-cancer drug (atezolizumab). Researchers want to find the safest dose of this new combination and then see if it works better at fighting the cancer than the standard chemotherapy and atezolizumab alone. This is an important step to find new and potentially more effective ways to treat this aggressive cancer in people who have recently been diagnosed.

Överblick

Status
Aktiv men inte rekryterande
Fas
FAS1, FAS2
Sponsor
Novartis Läkemedel
Inskrivningsmål
55
Starta
13 jul 2022
Beräknad slutförande
07 Mar 2028

Vad handlar denna studie om?

This study is investigating a new treatment approach for Extensive Stage Small Cell Lung Cancer (ES-SCLC). This is a fast-growing type of lung cancer, and doctors are always looking for better ways to treat it. The new treatment involves a special type of medicine called [177Lu]Lu-DOTA-TATE, which is a radioactive drug designed to target cancer cells. This drug will be given alongside atezolizumab and a standard chemotherapy combination of carboplatin and etoposide.

The main goals of this research are twofold. First, the study needs to find the safest and most tolerable dose of this new combination treatment. This is very important to make sure patients can receive the treatment without too many side effects. Second, once a safe dose is found, the study will compare this new combination directly to the current standard treatment (carboplatin, etoposide, and atezolizumab) to see if it is more effective at treating the cancer. The hope is that this new combination could offer a better way to fight this aggressive cancer.

Taking part in this study could offer you access to a new treatment that isn't widely available yet. It's a key step in understanding if this new approach can improve the lives of people with ES-SCLC. The study is designed to carefully monitor participants and gather information to help future patients.

Viktiga punkter

  • Tests a new combination treatment for ES-SCLC.
  • Aims to find a safe dose and improve cancer outcomes.
  • Compares a new drug with standard chemotherapy and immunotherapy.
  • Involves a screening, treatment, and follow-up period.
  • Participation is voluntary and you can withdraw anytime.

Vem kan vara berättigad?

To join this study, you must be at least 18 years old and have been diagnosed with Extensive Stage Small Cell Lung Cancer (ES-SCLC). Your cancer should be 'measurable,' meaning doctors can see and track it, and you shouldn't have had previous treatments for ES-SCLC, apart from possibly your very first round of chemotherapy. Your general health, as assessed by a doctor, should be good enough to take part, and you should be expected to live for at least six more months.

There are also some reasons why you might not be able to join. For example, if you've already had certain types of anti-cancer treatments that affect your immune system, or if you have serious ongoing infections like tuberculosis, hepatitis B, or hepatitis C. Also, if you have certain heart problems, severe autoimmune diseases, or allergies to any of the study medications, you wouldn't be able to participate. You also shouldn't be involved in another medical study at the same time.

Kan denna studie passa dig?

Svara på dessa snabba frågor för att se om du kan vara berättigad. Detta är endast en vägledning — forskarteamet fattar det slutgiltiga beslutet.

  1. Är du 18 år eller äldre?
  2. Do you have a diagnosis of Extensive Stage Small Cell Lung Cancer?
  3. Have you had very little or no previous treatment for your ES-SCLC?
  4. Är du i allmänhet tillräckligt frisk för att delta i en studie?
Svara på varje fråga för att se ditt resultat.

Vad innebär deltagande?

If you decide to take part, the study will involve several stages. First, there's a screening period of up to 28 days to check if the treatment is right for you, including a special scan to look at your cancer. Then, you'll enter the treatment period, which has two parts: an 'Induction' phase followed by a 'Maintenance' phase. During the early part of the study, different groups of participants will receive different doses of the new treatment to find the safest level. Once a safe dose is found, about 140 participants will be randomly assigned to either receive the new combination treatment or the current standard treatment. After the treatment period, there will be a follow-up period where doctors will continue to monitor your health. The total duration of your participation will depend on the stage of the study and how your body responds to the treatment.

Potentiella risker och fördelar

Potential benefits of joining this study include receiving a new experimental treatment for your cancer, which might be more effective than current options, and contributing to medical knowledge that could help future patients. However, like all medical treatments, there are potential risks and side effects associated with the drugs being used. The research team will carefully monitor you for any side effects, and you'll receive the best possible care. You have the right to withdraw from the study at any time, for any reason, without it affecting your usual medical care.

Platser (27)

  • AdventHealth
    Verifierat postnummer
    Orlando, USA
  • University Cancer and Blood Center LLC
    Verifierat postnummer
    Athens, United States
  • University of Kentucky
    Verifierat postnummer
    Lexington, USA
  • St Louis University
    Verifierat postnummer
    St Louis, USA
  • Hackensack University Medical Ctr
    Verifierat postnummer
    Hackensack, USA
  • University Hospitals Of Cleveland
    Verifierat postnummer
    Cleveland, USA
  • Fox Chase Cancer Center
    Verifierat postnummer
    Philadelphia, USA
  • Novartis Undersökningsplats
    Verifierat postnummer
    Wien, Österrike
  • Novartis Undersökningsplats
    Verifierat postnummer
    Montreal, Kanada
  • Novartis Undersökningsplats
    Verifierat postnummer
    Peking, Kina
  • Novartis Undersökningsplats
    Verifierat postnummer
    Shanghai, China
  • Novartis Undersökningsplats
    Verifierat postnummer
    Olomouc, Tjeckien

Vanliga frågor

What is Extensive Stage Small Cell Lung Cancer (ES-SCLC)?

It's an aggressive type of lung cancer that has spread from where it started to other parts of the body.

Vad är [177Lu]Lu-DOTA-TATE?

It's an experimental anti-cancer drug that uses a small amount of radiation to target and treat cancer cells.

Will I definitely get the new treatment if I join?

Not necessarily. In the main part of the study, participants are randomly assigned to either receive the new combination or the standard treatment, like flipping a coin.

Hur länge kommer jag att vara med i studien?

The study involves a screening period, a treatment period (with induction and maintenance phases), and a follow-up period. The total time can vary for each person.

Kan jag lämna studien när som helst?

Yes, you are free to leave the study at any time, for any reason, without it affecting your medical care.

Hur du får reda på mer

Prata alltid med din läkare eller specialist innan du bestämmer dig för att delta i en studie.

Diskussion

Gemenskapsdiskussion

Drivs av vårt forum på community.patient.info. Var vänlig och respektfull — detta är inte medicinsk rådgivning.